Novartis

Second phase III Novartis JAK inhibitor study meets primary endpoint

Tuesday, March 22, 2011 12:08 PM

Novartis said a pivotal phase III trial of the investigational Janus kinase (JAK) inhibitor INC424 (ruxolitinib) has met its primary endpoint of significantly reducing spleen size in patients with myelofibrosis (MF). INC424 is a potent, selective inhibitor of the JAK1 and JAK2 tyrosine kinases.

More... »

Bio-Ball fundraiser joins two communities working

Monday, March 21, 2011 08:00 AM

Can’t dribble, shoot or pass? Don’t worry. Everyone makes the team.

More... »

Novartis to cut 500 jobs in England

Thursday, March 17, 2011 12:33 PM

Novartis has announced plans to shed some 500 positions in the U.K. through an operational restructuring of its site in Horsham, West Sussex, England, according to PharmaTimes.

More... »

Teva: Doctors being contacted for trial of Copaxone copy

Wednesday, March 9, 2011 01:34 PM

Doctors are being contacted to organize a clinical trial for a copy of Teva Pharmaceutical’s multiple sclerosis medicine Copaxone, according to a report in FiercePharma.

More... »

Antisoma’s top management step down

Wednesday, March 2, 2011 08:20 AM

The top management of Antisoma has stepped down, as the British cancer specialist cut its operations following the failure of its two leading drug candidates, Reuters reported.

More... »

New $1b NIH center will tackle early-stage drug development to ease industry risk of failure

Monday, February 7, 2011 07:00 AM

A billion-dollar U.S. government drug development center, which will focus on moving potential new discoveries out of the lab and into early-phase trials, could help biopharmaceutical companies improve their success rate in developing new treatments by reducing the risk of failure in early-stage research.

More... »

Clinical Trial Activity in Russia Dipped in 2009

Friday, March 5, 2010 06:56 AM

According to Russia-based contract research organization (CRO) Synergy Research Group’s Annual Orange Report, Russia’s regulatory agency Federal Service on Surveillance in Healthcare and Social Development of the Russian Federation (RosZdravNadzor, RZN) approved 577 new clinical trials during 2009, 6% fewer than in 2008. Sixty percent, or 348 of the new studies, were multinational multi-center trials, down 4% from 2008.

More... »

CT Approvals Down, Global Participation Up in Russia Q2

Wednesday, September 2, 2009 07:19 AM

According to an Orange Paper released by Russia-based CRO, Synergy Research Group, Russia’s health agency, the Federal Service on Surveillance in Healthcare and Social Development (RosZdraNadzor, RZN) approved only 129 new clinical trials, including local and bioequivalence studies, during Q2 2009, representing a 17% decrease from Q2 last year. The percentage of approved multinational clinical trials increased slightly, however, to 65% of the total during this time period.

More... »

CenterWatch Monthly May 2009

Friday, May 1, 2009 11:00 AM

U.S. Sites Rate Novo Nordisk, Novartis and Eisai as Top Sponsors in 2009

More... »

Fighting The Logjam In LatAm Drug Trials

Monday, September 18, 2006 10:24 AM

Clinical research in Latin America has grown significantly over the past 10 years but obstacles to continued growth still exist. In our first-ever survey of investigative sites in Latin America, we at Thomson CenterWatch found that bottlenecks at the site level continue to hinder growth of clinical research in the region as researchers strive to improve the system.

More... »